Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses

Analytical Biochemistry

Volumn 423, Issue 2, 2012, Pages 261-268

  Stamova, Slava ^a   Feldmann, Anja ^a   Cartellieri, Marc ^a   Arndt, Claudia ^a   Koristka, Stefanie ^a   Apel, Falko ^a   Wehner, Rebekka ^a   Schmitz, Marc ^a   Bornhäuser, Martin ^b   Von Bonin, Malte ^b   Ehninger, Gerhard ^b   Bartsch, Holger ^a   Bachmann, Michael ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Bispecific antibodies; CD33; La antigen; Retargeting; Tumor immunology

Indexed keywords

ANTIBODIES; ANTIGENS; DISEASES; FLUORESCENCE; STEM CELLS; T-CELLS; TUMORS; UROLOGY;

ACUTE MYELOID LEUKEMIA; CD33; FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN FUSION; PROSTATE CANCER CELLS; RETARGETING; TUMOR IMMUNOLOGIES;

CYTOLOGY;

BISPECIFIC ANTIBODY; CD3 ANTIGEN; CD33 ANTIGEN; CHROMIUM 51; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; LA ANTIGEN; MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; EFFECTOR CELL; EPIFLUORESCENCE MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR IMMUNOLOGY;

EID: 84858996878     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.12.042     Document Type: Article

References (42)

1. S. Ménard, S. Canevari, M.I. Colnaghi, Hybrid antibodies in cancer diagnosis and therapy, Int. J. Biol. Markers 4 (1989) 131-134. (Pubitemid 19265887)
2. H. Lindhofer, R. Mocikat, B. Steipe, S. Thierfelder, Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas: implications for a single-step purification of bispecific antibodies, J. Immunol. 155 (1995) 219-225.
3. R.E. Bird, B.W. Walker, Single chain antibody variable regions, Trends Biotechnol. 9 (1991) 132-137. (Pubitemid 121003095)
4. P. Holliger, P.J. Hudson, Engineered antibody fragments and the rise of single domains, Nat. Biotechnol. 23 (2005) 1126-1136. (Pubitemid 41486394)
5. P. Holliger, G. Winter, Engineering bispecific antibodies, Curr. Opin. Biotechnol. 4 (1993) 446-449. (Pubitemid 23250384)
6. S.M. Kipriyanov, Generation of bispecific and tandem diabodies, Methods Mol. Biol. 562 (2009) 177-193.
7. B. Barat, S.J. Sirk, K. McCabe, J. Li, E.J. Lepin, R. Remenyi, A.L. Koh, T. Olafsen, S.S. Gambhir, S. Weiss, A.M. Wu, Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection, Bioconjug. Chem. 20 (2009) 1474-1481.
8. S.J. Sirk, T. Olafsen, B. Barat, K.B. Bauer, A.M. Wu, Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2, Bioconjug. Chem. 19 (2008) 2527-2534.
9. P. Bühler, P. Wolf, D. Gierschner, I. Schaber, A. Katzenwadel, W. Schultze-Seemann, U. Wetterauer, M. Tacke, M. Swamy, W.W. Schamel, U. Elsässer-Beile, A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell-mediated lysis of prostate cancer cells, Cancer Immunol. Immunother. 57 (2008) 43-52.
10. J. Kriangkum, B. Xu, L.P. Nagata, R.E. Fulton, M.R. Suresh, Bispecific and bifunctional single chain recombinant antibodies, Biomol. Eng. 18 (2001) 31-40. (Pubitemid 32776592)
11. R.E. Kontermann, Recombinant bispecific antibodies for cancer therapy, Acta Pharmacol. Sin. 26 (2005) 1-9. (Pubitemid 40093233)
12. P.A. Baeuerle, C. Reinhardt, Bispecific T-cell engaging antibodies for cancer therapy, Cancer Res. 15 (2009) 4941-4944.
13. K. Fortmüller, K. Alt, D. Gierschner, P. Wolf, V. Baum, N. Freudenberg, U. Wetterauer, U. Elsässer-Beile, P. Bühler, Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody, Prostate 71 (2011) 588-596.
14. A. Feldmann, S. Stamova, C.C. Bippes, H. Bartsch, R. Wehner, M. Schmitz, A. Temme, M. Cartellieri, M. Bachmann, Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats, Prostate 71 (2011) 998-1011.
15. C.C. Bippes, A. Feldmann, S. Stamova, M. Cartellieri, A. Schwarzer, R. Wehner, M. Schmitz, E.P. Rieber, S. Zhao, K. Schäkel, A. Temme, R.H. Scofield, B.T. Kurien, H. Bartsch, M. Bachmann, A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs), PLoS One 6 (2011) e16315.
16. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers, M. Schmidt, G. Riethmüller, C. Reinhardt, P.A. Baeuerle, P. Kufer, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science 321 (2008) 974-977.
17. S. d'Argouges, S. Wissing, C. Brandl, N. Prang, R. Lutterbuese, A. Kozhich, J. Suzich, M. Locher, P. Kiener, P. Kufer, R. Hofmeister, P.A. Baeuerle, R.C. Bargou, Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells, Leuk. Res. 33 (2009) 465-473.
18. B. Blanco, P. Holliger, R.G. Vile, L. Alvarez-Vallina, Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells, J. Immunol. 171 (2003) 1070-1077. (Pubitemid 36871424)
19. B. Cochlovius, S.M. Kipriyanov, M.J. Stassar, O. Christ, J. Schuhmacher, G. Strauss, G. Moldenhauer, M. Little, Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells, J. Immunol. 165 (2000) 888-895. (Pubitemid 30484756)
20. T. Dreier, P.A. Baeuerle, I. Fichtner, M. Grün, B. Schlereth, G. Lorenczewski, P. Kufer, R. Lutterbüse, G. Riethmüller, P. Gjorstrup, R.C. Bargou, T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, J. Immunol. 170 (2003) 4397-4402.
21. S. Stamova, M. Cartellieri, A. Feldmann, C.C. Bippes, H. Bartsch, R. Wehner, M. Schmitz, M. von Bonin, M. Bornhäuser, G. Ehninger, E.P. Rieber, M. Bachmann, Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells, Leukemia 25 (2011) 1053-1056.
22. S. Stamova, M. Cartellieri, A. Feldmann, C. Arndt, S. Koristka, H. Bartsch, C.C. Bippes, R. Wehner, M. Schmitz, M. von Bonin, M. Bornhäuser, G. Ehninger, M. Bachmann, Unexpected recombinations in single-chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module, Mol. Immunol. 49 (2011) 474-482.
23. T. Osada, D. Hsu, S. Hammond, A. Hobeika, G. Devi, T.M. Clay, H.K. Lyerly, M.A. Morse, Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody, Br. J. Cancer 102 (2010) 124-133.
24. M. Amann, K. Brischwein, P. Lutterbuese, L. Parr, L. Petersen, G. Lorenczewski, E. Krinner, S. Bruckmeier, S. Lippold, R. Kischel, R. Lutterbuese, P. Kufer, P.A. Baeuerle, B. Schlereth, Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3, Cancer Res. 68 (2008) 143-151. (Pubitemid 351380115)
25. C. Haas, E. Krinner, K. Brischwein, P. Hoffmann, R. Lutterbüse, B. Schlereth, P. Kufer, P.A. Baeuerle, Mode of cytotoxic action of T cell-engaging BiTE antibody MT110, Immunobiology 214 (2009) 441-453.
26. D. Nagorsen, P.A. Baeuerle, Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab, Exp. Cell Res. 317 (2011) 1255-1260.
27. 2/day is tolerable and highly effective, Blood 116 (2010) (American Society of Hematology abstract 2880).
28. M.S. Topp, G. Zugmaier, N. Goekbuget, S. Neumann, H. Horst, T. Raff, M. Brueggemann, M. Kneba, A. Viardot, M. Schmid, M. Schaich, M. Stelljes, M. Goebeler, H. Pfeiffer, O. Ottmann, T. Burmeister, E. Degenhard, M. Schmidt, J. Scheele, H. Einsele, P. Kufer, M. Klinger, D. Nagorsen, D. Hoelzer, R. Bargou, CD19/CD3 bispecific antibody blinatumomab (MT103) is highly effective in treatment of patients with minimal residual disease (MRD) from chemotherapy-resistant B-precursor acute lymphoblastic leukemia, Blood 116 (2010) (American Society of Hematology abstract 174).
29. M.S. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H.A. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, E. Degenhard, R. Köhne-Volland, M. Brüggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, M. Schmidt, R. Lutterbuese, C. Reinhardt, P.A. Baeuerle, M. Kneba, H. Einsele, G. Riethmüller, D. Hoelzer, G. Zugmaier, R.C. Bargou, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J. Clin. Oncol. 29 (2011) 2493-2498.
30. I. Herrmann, P.A. Baeuerle, M. Friedrich, A. Murr, S. Filusch, D. Rüttinger, M.W. Majdoub, S. Sharma, P. Kufer, T. Raum, M. Münz, Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells, PLoS One 5 (2010) e13474.
31. S. Offner, R. Hofmeister, A. Romaniuk, P. Kufer, P.A. Baeuerle, Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells, Mol. Immunol. 43 (2006) 763-771. (Pubitemid 41785405)
32. H.H. Gerdes, C. Kaether, Green fluorescent protein: applications in cell biology, FEBS Lett. 24 (1996) 44-47. (Pubitemid 26227423)
33. J.L. Casey, A.M. Coley, L.M. Tilley, M. Foley, Green fluorescent antibodies: novel in vitro tools, Protein Eng. 13 (2000) 445-452. (Pubitemid 30450105)
34. C. Bluemel, S. Hausmann, P. Fluhr, M. Sriskandarajah, W.B. Stallcup, P.A. Baeuerle, P. Kufer, Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen, Cancer Immunol. Immunother. 59 (2010) 1197-1209.
35. A. Morgenroth, M. Cartellieri, M. Schmitz, S. Gunes, B. Weigle, M. Bachmann, H. Abken, E.P. Rieber, A. Temme, Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells, Prostate 67 (2007) 1121-1131. (Pubitemid 46983341)
36. A. Jacks, J. Babon, G. Kelly, I. Manolaridis, P.D. Cary, S. Curry, M.R. Conte, Structure of the C-terminal domain of human La protein reveals a novel RNA recognition motif coupled to a helical nuclear retention element, Structure 11 (2003) 833-843. (Pubitemid 36830847)
37. M. Carmo-Fonseca, K. Pfeifer, H.C. Schröder, M.F. Vaz, J.E. Fonseca, W.E. Müller, M. Bachmann, Identification of La ribonucleoproteins as a component of interchromatin granules, Exp. Cell Res. 185 (1989) 73-85. (Pubitemid 19284956)
38. C.E. Hagemeyer, C. von Zur Muhlen, D. von Elverfeldt, K. Peter, Single-chain antibodies as diagnostic tools and therapeutic agents, Thromb. Haemost. 101 (2009) 1012-1019.
39. H. Zhao, K. Cui, A. Muschenborn, S.T. Wong, Progress of engineered antibody-targeted molecular imaging for solid tumors, Mol. Med. Rep. 1 (2008) 131-134.
40. K. Leung, Radioiodinated T84.66 minibody, in: Molecular Imaging and Contrast Agent Database (MICAD) [internet], National Center for Biotechnology Information (NCBI), Bethesda, MD, updated 3 April 2008.
41. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody, J. Nucl. Med. 48 (2007) 304-310.
42. M. Salavatifar, S. Amin, Z.M. Jahromi, N. Rasgoo, N. Rastgoo, M. Arbabi, Green fluorescent-conjugated anti-CEA single chain antibody for the detection of CEA-positive cancer cells, Hybridoma 30 (2009) 229-238.